Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Interest Expense

Cost of servicing the company's debt during the period.

Zai Lab LimitedNASDAQ: ZLAB

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense grows, but more slowly than its trailing trend

Q2 FY2026 interest expense of $1.59M rose 25.8% year over year, behind the +46.0% change in trailing-twelve-month interest expense. Sequentially, it fell 3.1% from the prior quarter.

Context

  • Interest expense amounted to 1.1% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +25.8% toward the trailing-twelve-month pace of +46.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.59M-3.1% QoQ
Last fiscal yearDec 2025
$5.21M+131.1% YoY
LTMJun 2026
$5.99M+46.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.8%——
1 year+131.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
5.21M USD
Year-over-year change
+131.1%

Interest Expense vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +46.0% is the highest of 2, against a peer median of -18.4%.
  • Interest expense amounts to 1.3% of revenue for ZLAB, versus a peer median of 0.0%.
ZLAB Competitors
Interest Expense for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥52.6M CNY-18.4%-0.1%9.4%
ZLABZai Lab LimitedLTM Jun 2026$5.99M USD+46.0%—1.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 USD—+63.9%0.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD—+50.9%0.0%
Peer median (excluding ZLAB) —-18.4%+50.9%0.0%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.